Kestra Medical Technologies Ltd (KMTS) Stock AnalysisKMTSKestra Medical Technologies Ltd

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG. It operates in the Healthcare sector.

Kestra Medical Technologies is a good buy right now due to its impressive revenue growth of 60% year-over-year, reaching $31 million in Q1 2027, and a current price of $26.98, which is below the analyst price target of $30. Additionally, the gross margin has improved significantly to 56.5%, indicating strong operational efficiency. The main risk is the net loss of $44.09 million reported for Q1 2027, which is a substantial increase from the previous year's loss.